{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:09:24Z","timestamp":1792631364373,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Intravitreal injection of conbercept (IVC) is a novel anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP). This study aimed to assess the intraocular pressure (IOP) effect of IVC.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> All IVC surgeries were performed in the Department of Ophthalmology, Guangdong Women and Children Hospital, from January 2021 to May 2021. In this study, 30 eyes of 15 infants who received intravitreal injections of conbercept at a dose of 0.25\u00a0mg\/0.025\u00a0mL were included. The IOP of all participants was measured prior to administering the injection and subsequently at 2\u00a0min, 1\u00a0h, 1\u00a0day, and 1\u00a0week thereafter.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We included 30 eyes (10 boys and 5 girls) with ROP. For the male group, the mean birth weight, mean gestational age at birth, and the mean time of postmenstrual age (PMA) at IVC treatment were 1,174.0 \u00b1 446.0\u00a0g, 28.4 \u00b1 3.0\u00a0weeks, and 37.1 \u00b1 1.6\u00a0weeks, respectively; for the female group, they were 1,108 \u00b1 285.5\u00a0g, 28.2 \u00b1 2.5\u00a0weeks, and 36.8 \u00b1 2.1\u00a0weeks, respectively. For the male group, the IOP at baseline, 2\u00a0min, 1\u00a0h, 1\u00a0day, and 1\u00a0week after IVC were 12.4 \u00b1 1.5\u00a0mmHg, 49.0 \u00b1 3.1\u00a0mmHg, 26.3 \u00b1 2.5\u00a0mmHg, 13.4 \u00b1 2.2\u00a0mmHg, and 11.6 \u00b1 1.7\u00a0mmHg, respectively; for the female group, they were 10.7 \u00b1 2.0\u00a0mmHg, 47.3 \u00b1 3.2\u00a0mmHg, 26.4 \u00b1 3.2\u00a0mmHg, 10.7 \u00b1 1.8\u00a0mmHg, and 10.2 \u00b1 1.8\u00a0mmHg, respectively. In both groups, the IOP immediately (2\u00a0min) after the operation was significantly higher than that at any other time point (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). IOP values returned to the preoperative baseline level on the first day after surgery, with no significant difference compared with that before injection (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). IOP continued to be maintained at the preoperative baseline level on the first week after surgery, with no significant difference compared with that before surgery (<jats:italic>p<\/jats:italic> &amp;gt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Infants with ROP who received IVC experienced a sharp increase in the IOP immediately after injection, which decreased to below 30\u00a0mmHg after 1\u00a0h and maintain that level for 1\u00a0week or longer.<\/jats:p>","DOI":"10.3389\/fphar.2023.1165356","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T13:21:35Z","timestamp":1685539295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity"],"prefix":"10.3389","volume":"14","author":[{"given":"Caifeng","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1177\/11206721211073405","article-title":"New trends in intravitreal anti-VEGF therapy for ROP","volume":"32","author":"Beccasio","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"B3","volume-title":"International classification of retinopathy of prematurityOphthalmology","author":"Chiang","year":"2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","journal-title":"Arch. Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12098-017-2404-3","article-title":"An update on retinopathy of prematurity (ROP)","volume":"84","author":"Dogra","year":"2017","journal-title":"Indian J. Pediatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq. Bras. Oftalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum. Dev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: Refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ophtha.2011.08.011","article-title":"Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections","volume":"119","author":"Hoang","year":"2012","journal-title":"Ophthalmology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10384-019-00661-y","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity","volume":"63","author":"Kato","year":"2019","journal-title":"Jpn. J. Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: A review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","article-title":"Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections","volume":"29","author":"Ladas","year":"2009","journal-title":"Retina"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12886-016-0255-8","article-title":"Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12888-020-02881-w","article-title":"Association of ocular diseases with schizophrenia, bipolar disorder, and major depressive disorder: A retrospective case-control, population-based study","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.1167\/iovs.13-12441","article-title":"Correlation between biomechanical responses of posterior sclera and IOP elevations during micro intraocular volume change","volume":"54","author":"Morris","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.2147\/OPTH.S229708","article-title":"Short-term changes in intraocular pressure after intravitreal injection of bevacizumab for the treatment of retinopathy of prematurity","volume":"13","author":"Obata","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1007\/s00417-021-05278-x","article-title":"Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity","volume":"259","author":"Ozdemir","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31348\/2019\/3\/1","article-title":"Influence of cornea on intraocular pressure measurement by ICARE PRO and ORA","volume":"75","author":"Pluh\u00e1\u010dek","year":"2019","journal-title":"Cesk. Slov. Oftalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1111\/j.1755-3768.2012.02412.x","article-title":"Central corneal thickness in full-term Saudi newborns","volume":"90","author":"Rushood","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ophtha.2015.12.019","article-title":"Neonatal risk factors for treatment-demanding retinopathy of prematurity: A Danish national study","volume":"123","author":"Slidsborg","year":"2016","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaapos.2011.04.004","article-title":"Intraocular pressure and central corneal thickness in premature and full-term newborns","volume":"15","author":"Uva","year":"2011","journal-title":"J. AAPOS."},{"key":"B23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70544","DOI":"10.1371\/journal.pone.0070544","article-title":"Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo","volume":"8","author":"Wang","year":"2013","journal-title":"PLOS ONE"},{"key":"B25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2014.5185","article-title":"Predictors for the development of referral-warranted retinopathy of prematurity in the telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study","volume":"133","author":"Ying","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for Type 1 retinopathy of prematurity in Zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.18240\/ijo.2022.12.12","article-title":"Long-term clinical effects of intravitreal injections of conbercept for the treatment of choroidal neovascularization in patients with pathological myopia","volume":"15","author":"Zhang","year":"2022","journal-title":"Int. J. Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1165356\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T13:21:37Z","timestamp":1685539297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1165356\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":27,"alternative-id":["10.3389\/fphar.2023.1165356"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1165356","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1165356"}}